482 ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking “don’t-eat-me” signal

CD24型 体内 流式细胞术 CD47型 抗体 巨噬细胞 癌症研究 化学 体外 吞噬作用 癌细胞 癌症 CD44细胞 分子生物学 免疫学 生物 医学 生物化学 内科学 生物技术
作者
Peng Chen,Min Deng,Yun Liu,Jiamei Luo,Rong Guo,Jay Mei,Bo Shan,Bing Hou
标识
DOI:10.1136/jitc-2022-sitc2022.0482
摘要

Background

By overexpressing anti-phagocytic surface proteins, often known as "don9t eat me" signals, cancer cells can evade macrophage-mediated elimination. Therapeutic antibodies targeting “don9t eat me” protein, such as CD47, demonstrates promising anti-tumor efficacy in preclinical models and in clinic. However, the clinical development of anti-CD47 mAbs that retain substantial FcR activating capacity (e.g. human IgG1) has been hampered by the on-target-off-tumor toxicity, such as erythrocyte depletion.1 CD24, a GPI-anchored, highly glycosylated surface protein interacting with Siglec-10 on innate immune cells, was reported to be a novel “don9t eat me” protein. CD24 is over-expressed in multiple tumor types. Knock-out of CD24 or blockade of CD24/Siglec-10 interaction enhances macrophage-mediated phagocytosis of tumor cells.2 In this study, we developed a first-in-class, humanized anti-CD24 antibody, ATG-031. The in vitro and in vivo anti-tumor activity of ATG-031 was evaluated in preclinical models.

Methods

The affinity of ATG-031 was measured using Surface Plasmon Resonance (SPR). Cell-based binding to HEK293, HEK293-CD24, human red blood cell (hRBC) and a panel of tumor cells was evaluated by flow cytometry. The ability of ATG-031 in enhancing macrophage-mediated phagocytosis of tumor cells was evaluated using human monocyte-derived M2 macrophage. in vivo efficacy of ATG-031 was test in mouse bearing MC38 murine syngeneic colorectal cancer cells stable-expressing human CD24 (MC38-hCD24). Expression profile of CD24 in human tumor and normal tissues were analyzed using TCGA/GTEx database or using an in-house developed companion diagnostic antibody on tissue microarray (TMA) by IHC staining.

Results

CD24 is overexpressed in multiple types of solid tumors and hematological malignancies. ATG-031 specifically binds to human CD24 with a single-digit nM affinity. ATG-031 potently binds to CD24-postive tumor cells, while showed no binding with parental HEK293 cells or hRBC. ATG-031 blocks the interaction between CD24 and Siglec-10 and induced potent macrophage-dependent tumor cell phagocytosis (figure 1A, B). Upon phagocytosis, M2 macrophages start to release M1-like cytokines suggesting a repolarization from M2 to M1. ATG-031 significantly inhibited in vivo tumor growth in MC38-hCD24 mouse model. A dose of 3mg/kg ATG-031 administered biweekly induced tumor regression (figure 1C).

Conclusions

Blocking CD24 by ATG-031 enhances macrophage-mediated phagocytosis of cancer cells, and polarized M2 macrophage towards anti-tumor M1 subtype (figure 2). It demonstrates potent in vivo anti-tumor tumor efficacy, suggesting promising therapeutic strategies against a broad range of solid tumor or hematological malignancies, which warrants further clinical investigation. A clinical study to investigate the safety and efficacy of ATG-031 in cancer patients is being developed.

References

Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα Immune Checkpoint. Immunity. 2020 May 19;52(5):742–752 Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019 Aug;572(7769):392–396.

Ethics Approval

This study was performed in strict accordance with institutional guidelines and approved by the Institutional Animal Care and Use Committee of the Shanghai Model Organisms Center, Inc. and the IACUC permit number was 2019-0011.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
幼儿园霸主完成签到,获得积分10
1秒前
老实的硬币完成签到,获得积分10
1秒前
YC完成签到,获得积分10
1秒前
Luminous发布了新的文献求助10
2秒前
无花果的应助被xxx采纳,获得10
2秒前
2秒前
香蕉觅云的应助被11采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
向连虎发布了新的文献求助10
5秒前
5秒前
5秒前
亮司完成签到,获得积分20
5秒前
ddd发布了新的文献求助10
5秒前
6秒前
7秒前
7秒前
7秒前
Ava的应助被现阶段回电话采纳,获得10
7秒前
Mnipwefjgj311发布了新的文献求助10
7秒前
WeL完成签到,获得积分10
8秒前
liukang172发布了新的文献求助50
9秒前
川川发布了新的文献求助10
9秒前
超帅的诗槐的应助被王志远采纳,获得30
10秒前
Lucas的应助被WangJiarou采纳,获得10
10秒前
10秒前
我姓阿叫杜关注了科研通微信公众号
10秒前
小甜甜完成签到,获得积分10
11秒前
珍珠完成签到,获得积分10
11秒前
初景发布了新的文献求助50
11秒前
李健的应助被nanjiren采纳,获得10
11秒前
12秒前
12秒前
HopeStar发布了新的文献求助20
12秒前
淼淼完成签到 ,获得积分10
13秒前
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155816
求助须知:如何正确求助?哪些是违规求助? 9552109
关于积分的说明 21708107
捐赠科研通 7744978
什么是DOI,文献DOI怎么找? 3426225
关于科研通互助平台的介绍 2551237
邀请新用户注册赠送积分活动 2469958